J C Henes1, H Schulze-Koops2, M Witt2, H P Tony3, F Mueller2, M Grunke2, M Czihal4, T Dörner5, F Proft6,7. 1. Abteilung für Onkologie, Hämatologie, klinische Immunologie, Rheumatologie, Pulmologie, Medizinische Klinik II, Universität Tübingen, Tübingen, Deutschland. 2. Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Klinikum, Universität München, München, Deutschland. 3. Abteilung für Rheumatologie und klinische Immunologie, Zentrum für Innere Medizin, Universitätsklinikum Würzburg, Würzburg, Deutschland. 4. Sektion Angiologie, Gefäßzentrum, Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, Universität München, München, Deutschland. 5. Abteilung für Rheumatologie, Medizinische Klinik m.S. Rheumatologie und klinische Immunologie, Charité Universitätsmedizin Berlin, Berlin, Deutschland. 6. Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Klinikum, Universität München, München, Deutschland. Fabian.Proft@charite.de. 7. Abteilung für Rheumatologie, Campus Benjamin Franklin, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland. Fabian.Proft@charite.de.
Abstract
OBJECTIVE: To evaluate the safety and clinical outcome of biological therapies in patients with large vessel vasculitis (LVV) or polymyalgia rheumatica (PMR) refractory to standard of care therapy in a real-life setting in Germany. METHODS: GRAID 2 (German Registry in Autoimmune Diseases 2) is a retrospective, noninterventional, multicenter registry collecting data from all patients with inflammatory rheumatic diseases refractory to conventional therapy treated with an initial off-label biological between August 2006 and December 2013. The retrospective documentation comprised case history, diagnosis, course of disease including safety and overall efficacy. RESULTS: Data from 14 patients were collected, 11 with LVV (78.6%) and 3 with isolated PMR (21.4%). Ten patients were treated with tocilizumab (71.4%), while 3 patients received infliximab infusions (21.4%) and 1 patient was treated with rituximab (7.1%). All clinical as well as laboratory efficacy parameters improved substantially. After the first application, tolerability of biologicals was assessed as "very good"/"good" by the physicians in 92.3% of the patients. Altogether, 8 adverse events (AEs) occurred in 4 patients including 3 infections (1 urogenital infection, 2 diverticulitis) representing a rate of 23.6 infections per 100 patient-years. One of these infections (diverticulitis under infliximab treatment) was rated as serious AE, requiring ICU treatment representing a rate of serious AEs of 7.9 per 100 patient-years. No deaths occurred during the observation period. CONCLUSION: With known limitations of a retrospective database, the results of this survey confirm data of smaller case series and proof-of-concept studies and suggest a substantial response to biological therapies in patients with otherwise refractory LVV or PMR with no new safety signals.
OBJECTIVE: To evaluate the safety and clinical outcome of biological therapies in patients with large vessel vasculitis (LVV) or polymyalgia rheumatica (PMR) refractory to standard of care therapy in a real-life setting in Germany. METHODS: GRAID 2 (German Registry in Autoimmune Diseases 2) is a retrospective, noninterventional, multicenter registry collecting data from all patients with inflammatory rheumatic diseases refractory to conventional therapy treated with an initial off-label biological between August 2006 and December 2013. The retrospective documentation comprised case history, diagnosis, course of disease including safety and overall efficacy. RESULTS: Data from 14 patients were collected, 11 with LVV (78.6%) and 3 with isolated PMR (21.4%). Ten patients were treated with tocilizumab (71.4%), while 3 patients received infliximab infusions (21.4%) and 1 patient was treated with rituximab (7.1%). All clinical as well as laboratory efficacy parameters improved substantially. After the first application, tolerability of biologicals was assessed as "very good"/"good" by the physicians in 92.3% of the patients. Altogether, 8 adverse events (AEs) occurred in 4 patients including 3 infections (1 urogenital infection, 2 diverticulitis) representing a rate of 23.6 infections per 100 patient-years. One of these infections (diverticulitis under infliximab treatment) was rated as serious AE, requiring ICU treatment representing a rate of serious AEs of 7.9 per 100 patient-years. No deaths occurred during the observation period. CONCLUSION: With known limitations of a retrospective database, the results of this survey confirm data of smaller case series and proof-of-concept studies and suggest a substantial response to biological therapies in patients with otherwise refractory LVV or PMR with no new safety signals.
Entities:
Keywords:
Biologicals; GRAID; Large vessel vasculitis; Off-label use; Polymyalgia rheumatica
Authors: Chie Miyabe; Yoshishige Miyabe; Klemen Strle; Nancy D Kim; John H Stone; Andrew D Luster; Sebastian Unizony Journal: Ann Rheum Dis Date: 2016-12-07 Impact factor: 19.103
Authors: Carol A Langford; David Cuthbertson; Steven R Ytterberg; Nader Khalidi; Paul A Monach; Simon Carette; Philip Seo; Larry W Moreland; Michael Weisman; Curry L Koening; Antoine G Sreih; Robert Spiera; Carol A McAlear; Kenneth J Warrington; Christian Pagnoux; Kathleen McKinnon; Lindsy J Forbess; Gary S Hoffman; Renée Borchin; Jeffrey P Krischer; Peter A Merkel Journal: Arthritis Rheumatol Date: 2017-03-08 Impact factor: 10.995
Authors: Carol A Langford; David Cuthbertson; Steven R Ytterberg; Nader Khalidi; Paul A Monach; Simon Carette; Philip Seo; Larry W Moreland; Michael Weisman; Curry L Koening; Antoine G Sreih; Robert Spiera; Carol A McAlear; Kenneth J Warrington; Christian Pagnoux; Kathleen McKinnon; Lindsy J Forbess; Gary S Hoffman; Renée Borchin; Jeffrey P Krischer; Peter A Merkel Journal: Arthritis Rheumatol Date: 2017-03-03 Impact factor: 10.995
Authors: Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: Christian Dejaco; Yogesh P Singh; Pablo Perel; Andrew Hutchings; Dario Camellino; Sarah Mackie; Andy Abril; Artur Bachta; Peter Balint; Kevin Barraclough; Lina Bianconi; Frank Buttgereit; Steven Carsons; Daniel Ching; Maria Cid; Marco Cimmino; Andreas Diamantopoulos; William Docken; Christina Duftner; Billy Fashanu; Kate Gilbert; Pamela Hildreth; Jane Hollywood; David Jayne; Manuella Lima; Ajesh Maharaj; Christian Mallen; Victor Martinez-Taboada; Mehrdad Maz; Steven Merry; Jean Miller; Shunsuke Mori; Lorna Neill; Elisabeth Nordborg; Jennifer Nott; Hannah Padbury; Colin Pease; Carlo Salvarani; Michael Schirmer; Wolfgang Schmidt; Robert Spiera; David Tronnier; Alexandre Wagner; Madeline Whitlock; Eric L Matteson; Bhaskar Dasgupta Journal: Ann Rheum Dis Date: 2015-10 Impact factor: 19.103
Authors: F Proft; H Schulze-Koops; M Grunke; E Schrezenmeier; F Halleck; J Henes; L Unger; E Schmidt; C Fiehn; A Jacobi; C Iking-Konert; C Kneitz; R E Schmidt; B Bannert; R E Voll; R Fischer-Betz; I Kötter; H P Tony; J Holle; M Aringer; A Erler; F Behrens; G R Burmester; T Dörner Journal: Z Rheumatol Date: 2018-02 Impact factor: 1.372